Company Overview
Erasca, Inc. operates as a clinical-stage precision oncology company dedicated to the discovery, development, and commercialization of novel therapies specifically designed for patients suffering from RAS/MAPK pathway-driven cancers. The company focuses its resources on creating molecular glue therapeutics, including the lead asset ERAS-0015, which targets RAS-mutated solid tumors to address a significant unmet medical need in oncology. This biotechnology entity functions within the broader Healthcare sector and the specialized Biotechnology industry, where capital allocation is typically directed toward high-risk research and development activities rather than immediate revenue generation. With a market capitalization of $4.74B and an employee base of 103, Erasca holds a valuation that is substantial relative to its current operational footprint, indicating that the market assigns significant value to its intellectual property and future clinical potential despite the lack of current sales revenue.
Financial Health
The company reports revenue of N/A, a net income of $-124,546,000, and an EBITDA of $-128,298,000, reflecting a stage where operating expenses heavily outweigh current commercial earnings. The substantial gap between the reported net income of $-124,546,000 and the EBITDA figure of $-128,298,000 suggests that non-operating expenses or interest costs are contributing to the overall loss, though the primary driver remains the high cost structure inherent in clinical-stage development. Free cash flow stands at $-66,761,124, which indicates that the company is consuming cash reserves to fund its research programs and operational overhead without generating positive cash flow from sales. The company holds $276.08M in cash against $47.14M in debt, creating a liquidity cushion that exceeds total liabilities, yet the financial position remains dependent on external capital markets or strategic partnerships. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a characteristic of early-stage biotechnology firms that have not yet achieved commercial scale or cost recovery from product sales. The balance sheet shows a debt-to-equity ratio of 14.50, which appears high but must be interpreted in the context of a cash-rich balance sheet where cash significantly outweighs debt obligations. The current ratio of 10.04 demonstrates an exceptionally strong short-term liquidity position, implying the company can easily meet its current liabilities with its existing current assets. Return on Equity is -33.3% and Return on Assets is -18.3%, revealing that management is currently burning capital to advance the pipeline rather than generating returns, a standard metric profile for clinical-stage entities before product approval.
Valuation Assessment
The trailing P/E ratio is listed as N/A due to the absence of earnings, while the forward P/E is calculated at -28.18, implying that the market is pricing the stock based on expected future earnings that are currently projected to be negative. The price-to-book ratio stands at 13.34, indicating that the market values the company at a significant premium over its tangible book value, likely reflecting the high value placed on its intangible assets such as patent portfolios and clinical trial data. The price-to-sales ratio is N/A and the EV/EBITDA is -35.18, suggesting that traditional sales-based or earnings-based valuation multiples are not applicable in the traditional sense for a company with no revenue and negative earnings. The stock has traded between a 52-week low of $1.01 and a 52-week high of $16.41, demonstrating a wide trading range that captures the volatility often seen in biotechnology stocks during clinical trial announcements or regulatory milestones. The beta of 1.17 indicates that the stock price is more volatile than the broader market, moving with greater intensity than the overall market index.
Growth & Income
Revenue growth year-over-year is N/A and earnings growth year-over-year is N/A, meaning that traditional growth metrics derived from historical financial performance cannot be calculated for a company currently in the clinical development phase without commercial sales. Since the company is not a dividend payer, the dividend yield is N/A and the payout ratio is 0.0%, which confirms that Erasca reinvests all available capital and generated cash flows back into research and development rather than distributing income to shareholders. This reinvestment strategy is typical for biotechnology firms aiming to advance their pipeline through clinical trials to achieve market entry and commercialization. Consequently, the overall growth and income profile for Erasca is defined entirely by the potential for future value creation from its therapeutic candidates rather than current cash distributions or revenue expansion, as the business model relies on successful clinical outcomes to unlock value for investors.